Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Buprenorphine Taper and Naltrexone Maintenance for Prescription Opioid Abuse
NCT00719095Phase 2Completed
- Sponsor
- University of Vermont Medical Center
- Start
- Apr 2006
- Primary completion
- Mar 2010
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, randomised trial of buprenorphine in opioid use disorder (OUD) (3 arms), sponsored by University of Vermont Medical Center. Primary endpoint: Percentage of subjects abstinent from all opioids at 12 weeks. Started Apr 2006; status: completed.
02
Drugs
buprenorphine
03
Conditions
opioid use disorder (OUD)
Beyond the preview
Go deeper on NCT00719095.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00719095.